SynaptiQ™ Research & Evidence Base:
The Peer-Reviewed Science Behind
Personalised Neuromodulation

This landmark review synthesised the neurophysiological evidence linking qEEG oscillatory biomarkers to rTMS treatment response in MDD. The authors describe MDD as a syndrome of "thalamocortical dysrhythmia," characterised by persistent resonance of abnormal low-frequency oscillations arising from hyperpolarised thalamic relay cells. The review demonstrates that resting-state qEEG measures — particularly theta and alpha band power, coherence, and synchrony — serve as both diagnostic markers of MDD severity and prognostic predictors of rTMS treatment response. This work is foundational to the SynaptiQ™ protocol's use of pre-treatment qEEG profiling to individualise stimulation parameters.

A systematic review of EEG abnormalities across the autism spectrum, documenting the heterogeneity of electrophysiological presentations and establishing consistent patterns — including elevated theta power, reduced alpha coherence, and disrupted frontal connectivity — that serve as the neurophysiological targets for personalised stimulation in ASD populations.

This large-scale study established that ASD is associated with a statistically stable, reproducible pattern of qEEG spectral coherence abnormalities distinguishable from neurotypical controls. The reliable identification of this EEG signature provides the objective neurophysiological basis for the diagnostic phase of personalised neuromodulation protocols, and enables biweekly monitoring of treatment-induced changes in coherence patterns.

Demonstrated that resting-state EEG coherence — particularly reduced long-range frontal connectivity — serves as a valid and reliable index of cortical network dysregulation in ASD. This study provides the mechanistic rationale for targeting frontal connectivity restoration as a primary endpoint in personalised rTMS protocols for autism.

Confirmed the presence of systematic resting-state EEG abnormalities in ASD, including disruptions in multiple frequency bands, supporting the utility of qEEG as a treatment-sensitive biomarker that can be monitored longitudinally to track neuroplastic changes induced by personalised brain stimulation.

This study established EEG complexity measures — specifically modified multiscale entropy — as sensitive biomarkers for ASD risk, demonstrating that neurophysiological divergence from typical development is detectable through qEEG in infants before behavioural symptoms fully manifest. Supports early intervention paradigms using qEEG-guided neuromodulation.

Demonstrated characteristic qEEG abnormalities in PTSD — including altered alpha power distribution, increased right-hemispheric hyperarousal signatures, and disrupted interhemispheric coherence — providing the neurophysiological basis for targeted neuromodulation protocols designed to normalise the electrocortical consequences of traumatic stress.

Established that qEEG provides objective, quantifiable indices of neurophysiological disruption following mild traumatic brain injury — including altered coherence, phase lag, and amplitude patterns — supporting its use as a diagnostic and treatment-monitoring tool in TBI-associated symptomatology including PTSD.

Characterised the EEG profile of panic disorder, identifying specific spectral abnormalities — including elevated high-frequency activity and disrupted alpha suppression — that correlate with symptom severity and panic-specific pathophysiology, providing the electrophysiological substrate for targeted neuromodulation in anxiety spectrum presentations.

Demonstrated that distinct anxiety subtypes produce differentiated qEEG signatures in adolescent populations, underscoring the necessity of individual-level EEG profiling rather than diagnosis-based generalisation — directly supporting the SynaptiQ™ principle that personalised protocols outperform categorical, symptom-based approaches.

Synthesised the neurophysiological evidence establishing qEEG as an objective, sensitive measure of TBI-related cortical dysfunction across the spectrum of injury severity. Demonstrated that qEEG provides information inaccessible to structural neuroimaging in mild-to-moderate TBI, with direct implications for monitoring neuromodulation-induced recovery trajectories.

Established the relationship between individual alpha peak frequency (APF) and cognitive function in neurotypical adults, providing the foundational rationale for APF-guided TMS frequency calibration. The finding that individual APF is a stable, genetically-influenced trait underpins the SynaptiQ™ and MeRT approach of calibrating stimulation frequency to the patient's endogenous alpha frequency rather than applying a standardised stimulation parameter.

This review synthesised the systems neuroscience rationale for oscillatory modulation as a therapeutic strategy across neurological injury paradigms. By establishing the role of pathological oscillatory states — including abnormal delta, theta, and alpha dynamics — as primary mediators of cognitive and functional deficits following brain injury, the review provides the theoretical framework connecting qEEG-identified frequency abnormalities to rTMS-mediated therapeutic normalisation.

Demonstrated that pre-treatment qEEG oscillatory profiles predict TMS treatment response in MDD, providing the evidence base for using qEEG not merely as a diagnostic tool but as a dynamic treatment-guidance instrument. Patients whose baseline qEEG showed specific alpha and theta frequency signatures demonstrated differential response to left versus right prefrontal stimulation, directly supporting the SynaptiQ™ protocol's use of individualised frequency and hemisphere selection.

As detailed in Section 01 above. In the clinical evidence context, this study provides the neurophysiological rationale for qEEG-guided personalisation: given that MDD manifests as a distributed, patient-specific pattern of oscillatory dysregulation rather than a uniform frontal asymmetry, effective treatment must target the individual's specific frequency-domain abnormalities rather than a population-average protocol.

A randomised, double-blind, sham-controlled trial of individualised electromagnetic treatment in PTSD, directly evaluating the personalised approach against placebo. The sham-controlled design controls for non-specific effects of treatment expectancy and physical contact, isolating the therapeutic signal attributable to the active personalised stimulation protocol.

Clinical documentation of the efficacy of EEG-guided personalised magnetic resonance therapy in combat-related PTSD — one of the most severe and treatment-resistant presentations of the disorder. Published through the Aerospace Medical Association, which provides rigorous peer review for military and occupational medicine research, this study underscores the applicability of personalised neuromodulation across the full severity spectrum of PTSD.

A rigorous sham-controlled trial evaluating low-frequency rTMS targeting the right dorsolateral prefrontal cortex in PTSD, demonstrating statistically significant reductions in PTSD symptom severity versus sham stimulation. Provides controlled evidence that the cortical targets and frequency parameters used in personalised PTSD protocols produce genuine therapeutic effects beyond placebo.

One of the earliest rigorous RCTs establishing right DLPFC rTMS as an effective intervention in PTSD. The double-blind, placebo-controlled design and publication in the American Journal of Psychiatry — one of the field's highest-impact journals — provides foundational evidence supporting the neuroanatomical targeting rationale for PTSD-specific personalised rTMS protocols.

This follow-up study documented sustained and continued behavioural improvements in ASD patients following non-invasive personalised transcranial magnetic stimulation with customised frequency modulation. The follow-up design is critical: it confirms that improvements are durable beyond the active treatment period — a key characteristic of neuroplastic rather than merely symptomatic therapeutic effects — and that customised frequency modulation produces clinically meaningful outcomes in a real-world ASD population.

Evaluated the clinical potential of EEG-guided magnetic resonance therapy across a paediatric ASD population, documenting improvements in core autism symptom domains — including social communication, sensory tolerance, and repetitive behaviours — following personalised neuromodulation protocols. Provides theoretical and clinical rationale for the expansion of qEEG-guided personalised TMS into paediatric ASD practice.

Reviewed the mechanistic and clinical evidence base for direct brain stimulation across neurological and psychiatric disorders including Parkinson's disease, establishing the foundational principles of neuromodulatory intervention — precision targeting, frequency specificity, and neuroplastic outcomes — that translate directly to the non-invasive rTMS protocols employed by SynaptiQ™.

Systematic review and meta-analysis establishing the evidence base for targeted neuromodulation in Tourette syndrome, demonstrating the broader applicability of brain stimulation approaches — including the frequency-specific, circuit-targeted principles underlying SynaptiQ™ — across complex neurological and neurodevelopmental conditions with established network dysregulation pathology.

Reviewed the evidence and future directions for targeted brain stimulation in bipolar disorder, with particular relevance to the neuromodulation of prefrontal-limbic circuits implicated in mood dysregulation. The review contextualises rTMS and personalised neuromodulation within the broader landscape of brain stimulation approaches to affective disorders, highlighting the convergent neuroanatomical targets shared across invasive and non-invasive modalities.

Case documentation of the application of EEG-guided magnetic resonance therapy in patients in minimally conscious states, demonstrating the extreme range of clinical contexts in which personalised neuromodulation can be applied. The cases illustrate that even in severely impaired neurological conditions, qEEG-guided stimulation protocols can produce clinically meaningful responses — underscoring the fundamental principle that the brain retains neuroplastic capacity across a wide spectrum of conditions when stimulation is appropriately calibrated to the individual's residual oscillatory activity.

Research by Fingelkurts et al. (2006), Duffy et al. (2012), Todder et al. (2012), Bosl et al. (2011), and multiple independent groups has established that qEEG reliably identifies condition-specific and individual-specific patterns of oscillatory dysregulation across MDD, ASD, PTSD, anxiety, and TBI — patterns that are sensitive to treatment-induced change and therefore applicable as both diagnostic and monitoring instruments.

The mechanistic studies of Hamidi et al. (2009) and the Current Biology entrainment study (2011) established that rTMS operates by biasing endogenous cortical oscillations toward target frequencies — providing the mechanistic rationale for calibrating stimulation frequency to the patient's individual alpha peak frequency (APF) as identified through qEEG, rather than applying a standardised frequency parameter.

Across MDD (Carpenter et al., 2012; Leuchter et al., 2013), PTSD (Taghva et al., 2015; Cohen et al., 2004; Nam et al., 2013), and ASD (Kim et al., SBMT; AANS follow-up), personalised and standard rTMS protocols demonstrate statistically significant improvements in validated clinical outcome measures. Where personalised protocols have been directly compared to standardised approaches, the evidence consistently favours individualisation.

The concurrent demonstration of clinical symptom improvement and objective qEEG normalisation — as reported by Taghva et al. (Trauma Monthly, 2015) and the SBMT pilot studies — confirms that qEEG monitoring is not merely an administrative adjunct to treatment, but a direct measure of the neuroplastic processes through which personalised neuromodulation produces its therapeutic effects. This dual-endpoint validation is the scientific basis for the SynaptiQ™ biweekly qEEG monitoring protocol.